MetaVia (MTVA) Stock Price

MetaVia Price

NASDAQ·CLOSED
1.41
​
Market closed

MetaVia stock price

Access this data via the Eulerpool API

MetaVia business model & stock analysis

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2016-08-05. The firm is focused on developing pharmaceuticals to treat neurodegenerative disorders. The firm is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The firm also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). The company also focused on developing capsule formulation of niclosamide for coronavirus indications.

Frequently asked questions about MetaVia

8 analysts currently rate the MetaVia stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the MetaVia share trades at 1.26 EUR (1.41 USD).

The MetaVia share (MTVA) is listed on 1 stock exchanges, including: NASDAQ (NRBO).

The revenue cannot currently be calculated for MetaVia.

The expected profit of MetaVia is -8.08 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of MetaVia is currently -0.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MetaVia stock.

The P/S cannot be calculated for MetaVia currently.

The Eulerpool Quality Score for MetaVia is 2/10.

The ISIN of MetaVia is US64132R5037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MetaVia is A2PXT4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MetaVia is MTVA. The ticker symbol is used to trade MetaVia shares on the stock exchange.

Fair ValueTerminal
1.23 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 5, 2016
ISIN
US64132R5037
Cusip
64132R107
Sedol
BKPFFV5
Market capitalization
4.53 M USDMicro Cap
52-Week Range
PEG
0.02
P/E ratio
P/Ee 2026
-0.40
P/Ee 2027
-0.43
P/Ee 2028
-0.64
P/Ee 2029
-0.74
P/Ee 2030
-0.80
P/S
P/Se
—
EV/EBIT
0.40
P/B Ratio
0.85
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-234.04 %
Last updated Oct 10, 2026, 4:47 PM

MetaVia Peer Group

MetaVia Ticker

NASDAQ · NRBO

All fundamentals and in-depth analysis of MetaVia

Our stock analysis for MetaVia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MetaVia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.